close

Sandoz Spin-off Updates, Comments On Gilenya Generics In Concentrate For Novartis Q3 Earnings

This came just after the Sandoz generic drug unit saw its international sales fall four% to US$7.11 billion in the very first nine months of 2021, generating it down 17% in the US . It has now been announced that the benefits of the critique suggest that a total split will be most useful to shareholders. Novartis announced its intention to separate Sandoz, its generics and biosimilars division into a new publicly traded standalone corporation, by way of a one hundred% spin-off. Mounting pressures from inflation, the war in Ukraine, and volatile stock markets will enhance the likelihood of a...